Cary Street Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cary Street Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-628	Closed	-$366K	–	1018
2025 Q4	$366K	Buy	+628	New	+$321K	0.01%	678

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cary Street Partners's MDGL Position: Q1 2026 in Review

Cary Street Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 628 shares — an estimated $366K sold.

Cary Street Partners first reported a position in MDGL in Q4 2025 and held it in 1 quarter. The position peaked at $366K in Q4 2025. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

Cary Street Partners reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Cary Street Partners sold 628 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $366K.
Cary Street Partners first reported a position in Madrigal Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Cary Street Partners's Madrigal Pharmaceuticals position peaked at $366K in Q4 2025.
380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Cary Street Partners's 13F filing for Q1 2026, filed 29 Apr 2026.